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Abstract
Background: The recognition, prevention and treatment of venous thromboembolism (VTE) remains a major
challenge in the face of the recent COVID-19 pandemic which has been associated with significant cardiovascular,
renal, respiratory and hematologic complications related to hypercoagulability. There has been little literature thus
far on the utility of screening ultrasound and the role of the clinical pharmacist in treating these patients.
Methods: We present a prospective pilot program of thirty-one consecutive COVID-19 patients who were provided
four extremity screening ultrasounds for VTE on admission. This was coordinated by a clinical pharmacist as part of
a multidisciplinary approach. Quantitative and qualitative data were recorded with the goal of describing the utility
of the clinical pharmacist in ultrasound screening. Data collected include demographics, information on clinical
symptoms or signs at presentation, and laboratory and radiologic results during the hospitalization from each
individual electronic medical record.
Results: Nine of the thirty-one patients presented with VTE. Of the nine patients, there were twenty-two total
clotted vessels, all of which were asymptomatic. The clinical pharmacist, as the coordinator for a multidisciplinary
COVID-19 associated coagulopathy management team, drafted a screening and treatment protocol for
anticoagulation prophylaxis and therapy of VTE after ultrasound findings.
Conclusion: VTE screening of hospitalized COVID-19 patients reveals a significant number of asymptomatic VTEs
and justifies diagnostic, prophylactic, and treatment measures coordinated by a clinical pharmacist.
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Background
Patients hospitalized due to an acute illness have an
elevated risk of venous thromboembolism (VTE) while
in-hospital and for up to 45 days after hospitalization
[1–9]. Patient survival is reduced significantly among
patients with VTE, especially after a pulmonary embol-
ism [10]. The risk of VTE in a patient with an acute in-
fectious disease rises up to 32 times that of the general
hospitalized patients in some reports [4, 5, 11]. This risk
is elevated in patients hospitalized due to COVID-19, yet
the level of risk is not clearly defined. Current laboratory
parameters--such as prothrombin time/international
normalized ratio, partial thromboplastin time, Clauss
Fibrinogen, and D-Dimer--lack sensitivity and specificity
for predicting VTE in COVID-19 patients [12–17]. We
hypothesize that not only severely ill COVID-19 patients
in the intensive care unit (ICU) are at risk of VTE, but
also that COVID-19 patients hospitalized to the general
floor can develop VTE without clinical signs or symptoms.
To date, there is scant literature regarding the
screening of extremities for VTE in COVID-19 patients
admitted to an ICU [12–17]. Moreover, there is no
current consensus regarding the criteria to predict those
patients who require standard, high-dose prophylactic,
or full anticoagulation treatment. Therefore, it was
decided to embark on a program of four extremity
screening ultrasound for all patients admitted to the
hospital with documented COVID-19. The coordination,
collection, and presentation of data was the responsibility
of the clinical pharmacist. The template for this multidis-
ciplinary team in addressing anticoagulation was derived
from trauma system models. In such models, the clinical
pharmacist’s duties include medication stewardship in
addition to the screening, diagnosis, and monitoring of
prophylactic and full anticoagulation treatment [18–21].
Coordinating ultrasound screening under the supervision
of a clinician gave the clinical pharmacist an additional
tool to help guide them in the management of anticoagu-
lation in COVID-19 patients along with daily D-dimer,
fibrinogen and other hematologic markers. The clinical
pharmacist would be the first to integrate knowledge of a
VTE into their care of patients and therefore they readily
took on this additional responsibility. Since the start of the
COVID-19 pandemic, experience from China, Europe and
the United States has revealed that clinical pharmacists
are essential for providing event-driven pharmaceutical
care which goes beyond routine activities such as medica-
tion review, prescription support, and patient counselling
[13, 14, 22–25]. Here, the coordination of four-extremity
screening ultrasound for all admitted COVID-19 patients
was added to the workload of the clinical pharmacist. In
addition, the clinical pharmacist was tasked with assisting
in the composition, editing and distribution of off-label
anticoagulation protocols for prophylaxis and treatment.
Under the supervision of the clinical pharmacist,
thirty-one consecutive patients admitted to the general
floor and the ICU were screened with four-extremity
ultrasound for VTE. Simultaneously the clinical pharma-
cist, along with a multidisciplinary team, defined the
incidence of VTE in our cohort of COVID-19 patients,
evaluated clinical and laboratory risk factors, and devel-
oped a treatment protocol. A similar screening and
treatment protocol development process, headed by
their respective clinical pharmacist, may be adopted by
all hospitals to provide comprehensive care for the
COVID-19 patient.
Methods
This study included patients with laboratory-confirmed
COVID-19 infection who were admitted between 28
April 2020 and 20 May 2020. Clinical specimens were
collected from a nasopharyngeal swab, sputum or bron-
chial aspirate. Diagnosis of COVID-19 infection was
made with the reverse-transcriptase–polymerase-chain-
reaction assay based on the World Health Organization
standard that targets the SARS-CoV-2 E gene and RdRp
gene [26]. Thirty-one adults (18 years of age or older)
were identified. There were no pregnant women or chil-
dren admitted to the ICU during the study period. The
study protocol was in accordance with the Declaration
of Helsinki and approved by the institutional review
board of St. Joseph Regional Medical Center Mishawaka.
Data collected includes demographics, information on
clinical symptoms or signs at presentation, and laboratory
and radiologic results during the hospitalization from each
individual electronic medical record. All laboratory tests
and additional radiologic assessments were performed at
the discretion of the attending physician.
A clinical pharmacist was appointed by a multidiscip-
linary team to coordinate their efforts in identifying and
treating COVID-19 patients with VTE. In concert with
the infectious disease specialist and hematologist, the
clinical pharmacist designed protocols for the ordering
of salient laboratory parameters for anticoagulation, as
well as criteria for extremity ultrasounds. The clinical
pharmacist ordered all ultrasounds of the extremities,
initiated and monitored anticoagulation agents, and also
assured that all coagulation tests were ordered for each
patient according to the defined protocol. Furthermore,
the clinical pharmacist, utilizing laboratory and ultrasound
findings, made anticoagulant adjustment recommendations.
Upper and lower limb venous compression ultrasound
(CUS) was systematically performed in all patients by in-
dependent vascular specialists within the first 2 days of
admission. The systematic CUS assessed proximal veins.
The criterion for establishing the diagnosis of VTE was
the lack of compressibility on B-mode ultrasound [27].
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Results
Thirty-one patients were screened during the initial
phase from 28 April until 20 May 2020. No patient in
whom screening ultrasound detected VTE had overt
symptoms defined as edema, erythema, or pain. VTE
was identified in nine (29%) patients. All nine (100%)
patients with identifiable VTE were asymptomatic. In
these nine patients, a total of twenty-two clotted vessels
were diagnosed (See Table 1). There were nine VTEs
noted in the extremities. None of these patients had a
peripherally inserted central catheter (PICC). None of
these patients were receiving anticoagulation prior to
COVID-19. Of these nine patients with asymptomatic
clots, five were admitted to the ICU and all five were
intubated. Demographic analysis of the patients is listed
in Table 2.
A protocol for prophylactic and therapeutic anticoagu-
lation was evaluated and revised on a weekly basis by
the clinical pharmacist in accordance with guidelines
published by the International Society of Hemostasis
and Thrombosis. A summary of the current protocol for
evaluation and treatment is shown in Fig. 1.
All medication administration was coordinated by the
clinical pharmacist. Patients in our study received VTE
prophylaxis with daily weight-based subcutaneous
enoxaparin or with unfractionated subcutaneous
heparin in daily or divided doses. Patients with anatom-
ically proven VTE were treated with weight based sub-
cutaneous enoxaparin, argatroban or with intravenous
(IV) unfractionated heparin. Finally, patients admitted
to the ICU without anatomic evidence of VTE were
treated with either intermediate doses of weight based
enoxaparin, argatroban or with therapeutic weight
based doses of IV unfractionated heparin.
There were no adverse events that occurred in this
group as a result of implementing this program among
patients with asymptomatic VTE.
Discussion
Recent evidence suggests that trauma-induced coagulopa-
thy may be comparable to the hypercoagulable nature of
COVID-19 patients [28, 29]. Post-resuscitation trauma pa-
tients are at high risk for developing VTE and multiorgan
failure due to a shock-induced endotheliopathy and fi-
brinolytic shutdown. Similar to trauma patients, the mor-
tality and outcome for COVID-19 patients may improve
with higher intensity VTE prophylaxis or full anticoagula-
tion to prevent the formation of micro thromboemboli in
the pulmonary vasculature [28–42]. COVID-19 coagulop-
athy, like trauma induced coagulopathy, is characterized
by a spectrum of hyper- to hypo-coagulable states in the
same patient. Even though our group of patients had no
adverse events, hemorrhage as a result of anticoagulation
in hospitalized COVID-19 patients was documented. The
use of thromboelastography (TEG) for monitoring antic-
oagulation in hospitalized COVID-19 patients has been
shown to be beneficial in guiding changes to anticoagula-
tion for these patients. TEG allows for the clinician to
make goal directed anticoagulation decisions on treatment
changes which reduces the incidence of hemorrhage [43].
Selection and intensity of anticoagulation in these patients
require a dynamic means of evaluation involving screen-
ing, prophylaxis, and treatment for VTE [13, 14, 44]. In
light of the similar coagulopathies of COVID-19 and
trauma patients, it is logical that both patient groups bene-
fit from the expert management of a clinical pharmacist.
In our hospital, the clinical pharmacist already coordi-
nated the administration of therapies such as antivirals,
convalescent plasma, targeted immunotherapy, and IV an-
tibiotics. The responsibilities of the clinical pharmacist
were expanded to include screening and treatment of
COVID-19 coagulopathies, including four extremity
screening ultrasound for VTE.
Recent data from the NIH ACTIV-4 study demon-
strated selective benefit of early anticoagulation for
COVID-19 patients. The finding of upper extremity
DVTs and/or asymptomatic DVTs would identify higher
risk COVID-19 patients in need of anticoagulation early
in the admission process. This same trial has demon-
strated the potential dangers of delayed anticoagulation
in severely ill COVID-19 patients which further in-
creases the importance of early CUS screening and close
anticoagulation management of these patients [43, 45].
Nine patients (29%) who received screening ultrasound
were found to have asymptomatic VTE despite no PICC
line, one of the strongest risk factors for upper extremity
clots. Significantly, this supports the hypercoagulopathic
state associated with COVID-19 and the need for an
Table 1 Localization of VTE on CUS
Anatomic localization of clot Clots, N = 22





Lower extremity 3 (13.6%)
Common femoral 1 (4.5%)
Posterior tibial 2 (9.1%)
Other 4 (18.2%)
Subclavian 1 (4.5%)
Internal jugular 1 (4.5%)
Common iliac 1 (4.5%)
Scrotal 1 (4.5%)
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Table 2 COVID-19 patient characteristics
Negative VTE (n = 22) Positive for VTE (n = 9) p-Value
Demographics
Age (years), mean (SD) 59.0 (17.2) 59.5 (14.5) –
Female, n (%) 7 (31.8%) 3 (33.3%) –
BMI (kg/m2), mean (SD) 31.3 (9.1) 32.7 (9.1) –
Prior anticoagulation therapy 0 (0.0%) 0 (0.0%) –
Comorbidities, n (%)
Hypertension 11 (50.0%) 2 (22.2%) 0.15
Cardiovascular disease 0 (0.00%) 4 (44.4%) 0.0008
COPD 2 (9.09%) 3 (33.3%) 0.10
OSA 1 (4.55%) 1 (11.1%) 0.50
Hepatitis 0 (0.00%) 1 (11.1%) 0.11
Peripheral vascular disease 1 (4.55%) 1 (11.1%) 0.50
Malignancy 1 (4.55%) 1 (11.1%) 0.50
Diabetes 9 (40.9%) 1 (11.1%) 0.10
Renal failure 1 (4.55%) 4 (44.4%) 0.006
Paraplegia 0 (0.00%) 1 (11.1%) 0.11
Singulitis 0 (0.00%) 1 (11.1%) 0.11
Disposition, n (%)
ICU 0 (0.00%) 5 (55.5%) 0.0001
Intubation 0 (0.00%) 5 (55.5%) 0.0001
Death no. 0 (0.00%) 1 (11.1%) 0.11
Fig. 1 Saint Joseph Regional Medical Center’s Recommended VTE Prophylaxis and Treatment for COVID-19 patients [1, 13, 14]
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evidence-based pharmacologic treatment protocol
[8–10, 13, 15, 16, 30, 46]. Recent literature from
China, Europe, and the United States has revealed an
expanding role for the clinical pharmacist given the evolv-
ing nature of guidelines for treating COVID-19 patients
[13, 14, 22–25]. Here, the clinical pharmacist drafted
guidelines employing ultrasound screening for VTEs to
guide anticoagulation therapy; the pharmacist’s role is
particularly important with increased off-label use of
medications during the COVID-19 pandemic.
Patients who screened positive for VTE were found to
have high rates of comorbidities including hypertension,
cardiovascular disease, chronic obstructive pulmonary dis-
ease and renal failure. This points to a potential adverse
additive effect of COVID-19 for those with preexisting
medical conditions. Among patients with a negative ultra-
sound screening for VTE, none were admitted to the ICU
or intubated (See Table 2). Five of the nine VTE positive
patients diagnosed by ultrasound screening were later ad-
mitted to the ICU, and each of those five patients were
also intubated. A high incidence of VTE in COVID-19 pa-
tients admitted to the ICU has recently been reported
[17]. Significantly, this demonstrates the importance of
having a clinical pharmacist guide screening and therapy
for the complex coagulopathy found in COVID-19
patients. With the findings in this study, the authors hope
to prompt similar utilization of pharmacists to prevent
clotting or bleeding complications in COVID-19 patients.
Conclusions
We present a pilot experience of a prospective evaluation
protocol for COVID-19 associated VTE coordinated by a
clinical pharmacist. This clinical pharmacist facilitated
COVID-19 patients’ ultrasound screening, diagnosis, and
monitoring of prophylactic and full anticoagulation
treatment [18–21]. This multidisciplinary team was
adapted from previous programs that utilized a similar dy-
namic for management of trauma-related anticoagulation
prophylaxis and treatment. Nine of thirty-one (29%)
COVID-19 patients had radiographic evidence of VTE
despite no clinical symptoms on initial presentation.
These results confirm the recent emphasis on aggressive
VTE prophylaxis and treatment due to the relatively high
risk of VTE in COVID-19 [13, 14]. Moreover, these results
support the importance of having a clinical pharmacist
coordinate screening ultrasound for VTE in COVID-19
patients and management of their anticoagulation. This
study demonstrates the dynamic and foundational role the
clinical pharmacist can play in the management of coagu-
lopathies in the COVID-19 patient.
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